Zacks Research Brokers Increase Earnings Estimates for WST

West Pharmaceutical Services, Inc. (NYSE:WST) – Stock analysts at Zacks Research raised their FY2025 earnings per share estimates for West Pharmaceutical Services in a report issued on Thursday, May 15th. Zacks Research analyst I. Bandyopadhyay now expects that the medical instruments supplier will post earnings of $6.26 per share for the year, up from their prior estimate of $6.18. The consensus estimate for West Pharmaceutical Services’ current full-year earnings is $6.62 per share. Zacks Research also issued estimates for West Pharmaceutical Services’ Q4 2025 earnings at $1.71 EPS, Q1 2026 earnings at $1.45 EPS, Q2 2026 earnings at $1.85 EPS, FY2026 earnings at $7.10 EPS and FY2027 earnings at $8.22 EPS.

Other equities analysts also recently issued reports about the stock. Stephens upgraded shares of West Pharmaceutical Services to a “strong-buy” rating in a report on Monday, April 21st. KeyCorp lowered their target price on West Pharmaceutical Services from $470.00 to $325.00 and set an “overweight” rating on the stock in a research note on Friday, February 14th. Deutsche Bank Aktiengesellschaft upgraded shares of West Pharmaceutical Services from a “hold” rating to a “buy” rating and set a $250.00 target price on the stock in a research report on Friday, February 14th. Evercore ISI began coverage on West Pharmaceutical Services in a report on Tuesday, March 18th. They set an “outperform” rating and a $275.00 target price on the stock. Finally, StockNews.com cut shares of West Pharmaceutical Services from a “buy” rating to a “hold” rating in a research report on Thursday, February 27th. Two equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $332.50.

West Pharmaceutical Services Trading Up 2.7%

West Pharmaceutical Services stock opened at $216.38 on Monday. The company has a debt-to-equity ratio of 0.08, a current ratio of 2.79 and a quick ratio of 2.23. The firm has a 50-day moving average of $214.89 and a 200-day moving average of $274.57. The company has a market cap of $15.55 billion, a price-to-earnings ratio of 32.34, a P/E/G ratio of 6.74 and a beta of 1.14. West Pharmaceutical Services has a one year low of $187.43 and a one year high of $355.66.

West Pharmaceutical Services (NYSE:WST) last released its earnings results on Thursday, April 24th. The medical instruments supplier reported $1.45 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.22 by $0.23. West Pharmaceutical Services had a return on equity of 18.60% and a net margin of 17.03%. The firm had revenue of $698.00 million during the quarter, compared to analysts’ expectations of $685.24 million. During the same quarter in the prior year, the company earned $1.56 EPS. The company’s revenue was up .4% on a year-over-year basis.

West Pharmaceutical Services Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, August 6th. Stockholders of record on Wednesday, July 30th will be given a dividend of $0.21 per share. This represents a $0.84 annualized dividend and a dividend yield of 0.39%. The ex-dividend date is Wednesday, July 30th. West Pharmaceutical Services’s dividend payout ratio (DPR) is 13.19%.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of WST. Whipplewood Advisors LLC bought a new stake in West Pharmaceutical Services during the 4th quarter valued at $25,000. Centricity Wealth Management LLC purchased a new stake in West Pharmaceutical Services in the 4th quarter valued at $35,000. Cornerstone Planning Group LLC lifted its stake in West Pharmaceutical Services by 57.1% during the 4th quarter. Cornerstone Planning Group LLC now owns 110 shares of the medical instruments supplier’s stock valued at $38,000 after acquiring an additional 40 shares in the last quarter. Zions Bancorporation National Association UT purchased a new position in West Pharmaceutical Services during the 1st quarter worth $25,000. Finally, Quarry LP purchased a new stake in shares of West Pharmaceutical Services in the first quarter valued at about $27,000. 93.90% of the stock is owned by institutional investors.

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.